Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

Immunome Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application 

Immunome Continues to Progress IMM-BCP-01 Towards Phase 1b Clinical Trial 

Ongoing Progress on Oncology Pipeline, Including Lead Program Targeting IL-38, a Novel Innate Immunome Checkpoint¬†–

See more here

Comments are closed.